Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $204.64.

Several research firms recently issued reports on ASND. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a report on Tuesday, February 18th. The Goldman Sachs Group increased their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Evercore ISI upped their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 18th. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, March 18th.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ascendis Pharma A/S during the 4th quarter worth approximately $28,000. Wilmington Savings Fund Society FSB bought a new position in Ascendis Pharma A/S during the 3rd quarter worth $30,000. Jones Financial Companies Lllp lifted its holdings in shares of Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after buying an additional 197 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 328 shares during the period. Finally, Groupama Asset Managment acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at about $60,000.

Ascendis Pharma A/S Stock Up 0.8 %

NASDAQ ASND opened at $155.86 on Tuesday. The firm’s 50 day moving average is $144.72 and its 200-day moving average is $137.63. The company has a market capitalization of $9.46 billion, a PE ratio of -21.95 and a beta of 0.62. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.